Sol-Gel Technologies, Inc.

Sol-Gel Technologies granted 180-day extension to meet Nasdaq's minimum bid price rule, plans to cure deficiency via reverse stock split if necessary. The company focuses on dermatology treatments, including Phase 3 trial for SGT-610 for Gorlin syndrome.

Sol-Gel Technologies appoints Mori Arkin as interim CEO from Jan 1, 2025; ongoing Phase 3 trial of SGT-610 for Gorlin Syndrome with 40+ sites; SGT-210 proof-of-concept study for Darier disease continues.

DelveInsight's 'Rosacea Pipeline Insight, 2024' report highlights 25+ key companies developing 25+ pipeline drugs for Rosacea, with therapies in various stages of clinical development. Key companies include Sol-Gel Technologies, Maruho Co., Ltd., AOBiome LLC, and others. Emerging therapies like Epsolay, M 1220, and BMX-010 are expected to impact the market. Regulatory approvals and collaborations are noted, such as Sol-Gel Technologies' agreement with Searchlight Pharma Inc. and Zydus Lifesciences' FDA approval for Metronidazole Topical cream.